a month ago
VTVT
AnalystsKambiz YazdiKambiz Yazdi's Stock Forecasts
AnalystsKambiz Yazdi
Sectors:
Industries:
Analyst Ranking
Top 24%
#1219 out of 5208 analysts
Average Return
+23.32%
Win Rate
67%12 out of 18
Risk vs Reward
Poor
Good
Kambiz Yazdi's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Praxis Precision Medicines IncPRAX | +213.27% | $15.15 | $47.46 | 2023-06-01 - 2024-05-31 | Strong Buy |
Avalo Therapeutics IncAVTX | +120.73% | $8.54 | $18.85 | 2025-03-24 - 2026-03-03 | Strong Buy |
Praxis Precision Medicines IncPRAX | +68.09% | $189.32 | $318.22 | 2025-11-18 - 2026-03-03 | Strong Buy |
Arcutis Biotherapeutics IncARQT | +52.36% | $15.49 | $23.60 | 2025-03-10 - 2026-03-03 | Strong Buy |
Arcutis Biotherapeutics IncARQT | +46.40% | $10.69 | $15.65 | 2024-08-27 - 2025-08-27 | Strong Buy |
Kambiz Yazdi Analyst Color
Get additional color on Kambiz Yazdi's coverage of popular stocks
2 months ago
PRAX
3 months ago
PRAX
Kambiz Yazdi's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Sionna Therapeutics IncSION | 4 | Strong Buy | $58.00 | +70.14% | Reiterates | 2 days ago |
Vtv Therapeutics IncVTVT | 2 | Strong Buy | $49.00 | +41.33% | Maintains | a month ago |
Praxis Precision Medicines IncPRAX | 5 | Strong Buy | $843.00 | +164.91% | Maintains | 2 months ago |
Rapport Therapeutics IncRAPP | 2 | Strong Buy | $47.00 | +68.76% | Reiterates | 3 months ago |
Avalo Therapeutics IncAVTX | 1 | Strong Buy | $23.00 | +22.02% | Initiates Coverage On | a year ago |
Arcutis Biotherapeutics IncARQT | 2 | Strong Buy | $19.00 | -19.49% | Maintains | a year ago |
Eyepoint IncEYPT | 1 | Strong Buy | $15.00 | N/A | Initiates Coverage On | 2 years ago |
Pmv Pharmaceuticals IncPMVP | 1 | Strong Buy | $5.00 | N/A | Initiates Coverage On | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.